GTx (United States)

GTx (United States)

GTx, Inc. was a pharmaceutical company working on drugs in the selective estrogen receptor modulator and selective androgen receptor modulator classes. Its drugs in development included enobosarm and GTx-758. The company was founded in Memphis in 1997 by Mitch Steiner and Marc S. Hanover. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for GTx (United States), United States, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

23%


Total
Publications

26K


Total Open
Publications

5.9K


Total
Citations

1M


Open Access
Percentage

23%


Total
Publications

26K


Total Open
Publications

5.9K


Total
Citations

1M

Wikipedia

Website

download

Breakdown

12% 5% 8% 75%

Publisher Open

12%

Both

5%

Other Platform Open

8%

Closed

75%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

02004006008001k1.2k1.4k1.6k1.8kTotal Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

39%OA Journal

OA Journal 39%

1.8K

Hybrid 26%

1.2K

No Guarantees 35%

1.6K

Other Platform Open

Domain 64%

2.3K

Institution 29%

1K

Other Internet 13%

476

Public 1%

52

Preprint 1%

39

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
2.3K
DOI
Other Internet
437
DANS - Data Archiving and Networked Services
Institution
173
Le Centre pour la Communication Scientifique Directe - HAL - Diderot
Institution
76
Europe PMC
Domain
59
Academy of Humanities and Economics in Lodz - Homo Politicus
Institution
57
University of Modena and Reggio Emilia - IRIS UNIMORE
Institution
50
Unknown Repository
Other Internet
41
Zenodo
Public
40
Yonsei University Medical Library - YUHSpace
Institution
38
1 / 20

Data updated 18 August 2025

Share

Share

Share